B. Riley Raises Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target to $236.00

Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price objective hoisted by B. Riley from $194.00 to $236.00 in a research note released on Tuesday morning,Benzinga reports. B. Riley currently has a neutral rating on the biopharmaceutical company’s stock. B. Riley also issued estimates for Madrigal Pharmaceuticals’ Q4 2024 earnings at ($3.86) EPS, FY2024 earnings at ($23.09) EPS, Q1 2025 earnings at ($3.34) EPS, Q2 2025 earnings at ($3.09) EPS, Q3 2025 earnings at ($2.86) EPS, Q4 2025 earnings at ($2.46) EPS, FY2025 earnings at ($11.72) EPS, FY2026 earnings at $15.22 EPS and FY2027 earnings at $32.42 EPS.

A number of other research firms also recently weighed in on MDGL. HC Wainwright reissued a “buy” rating and set a $390.00 price target on shares of Madrigal Pharmaceuticals in a research report on Tuesday, October 22nd. Oppenheimer decreased their price objective on shares of Madrigal Pharmaceuticals from $375.00 to $350.00 and set an “outperform” rating for the company in a report on Wednesday, October 23rd. StockNews.com raised shares of Madrigal Pharmaceuticals to a “sell” rating in a research report on Saturday, October 12th. Evercore ISI reduced their price target on shares of Madrigal Pharmaceuticals from $405.00 to $360.00 and set an “outperform” rating on the stock in a research report on Thursday, August 8th. Finally, Citigroup lowered their price objective on Madrigal Pharmaceuticals from $382.00 to $371.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, Madrigal Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $347.33.

Madrigal Pharmaceuticals Stock Performance

NASDAQ:MDGL opened at $350.70 on Tuesday. The firm has a 50-day moving average of $236.51 and a two-hundred day moving average of $246.83. The company has a debt-to-equity ratio of 0.15, a current ratio of 5.98 and a quick ratio of 5.93. The stock has a market cap of $7.65 billion, a P/E ratio of -13.98 and a beta of -0.46. Madrigal Pharmaceuticals has a 1-year low of $133.99 and a 1-year high of $368.29.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its quarterly earnings results on Thursday, October 31st. The biopharmaceutical company reported ($4.92) EPS for the quarter, beating analysts’ consensus estimates of ($6.94) by $2.02. The business had revenue of $62.18 million during the quarter, compared to analysts’ expectations of $34.60 million. During the same period in the prior year, the company posted ($5.34) EPS. On average, research analysts expect that Madrigal Pharmaceuticals will post -24.08 earnings per share for the current fiscal year.

Insider Transactions at Madrigal Pharmaceuticals

In related news, Director Richard S. Levy sold 5,000 shares of the business’s stock in a transaction that occurred on Friday, November 1st. The stock was sold at an average price of $300.94, for a total transaction of $1,504,700.00. Following the completion of the transaction, the director now owns 11,012 shares in the company, valued at $3,313,951.28. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, Director Richard S. Levy sold 5,000 shares of the stock in a transaction dated Friday, November 1st. The shares were sold at an average price of $300.94, for a total value of $1,504,700.00. Following the sale, the director now owns 11,012 shares of the company’s stock, valued at $3,313,951.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO William John Sibold sold 6,363 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $243.83, for a total transaction of $1,551,490.29. Following the transaction, the chief executive officer now directly owns 55,887 shares of the company’s stock, valued at $13,626,927.21. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 22.80% of the company’s stock.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MDGL. First Horizon Advisors Inc. grew its position in Madrigal Pharmaceuticals by 1,633.3% in the 2nd quarter. First Horizon Advisors Inc. now owns 104 shares of the biopharmaceutical company’s stock valued at $29,000 after buying an additional 98 shares in the last quarter. EntryPoint Capital LLC acquired a new stake in shares of Madrigal Pharmaceuticals in the 1st quarter worth approximately $41,000. Signaturefd LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 36.8% in the second quarter. Signaturefd LLC now owns 145 shares of the biopharmaceutical company’s stock valued at $41,000 after acquiring an additional 39 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of Madrigal Pharmaceuticals by 47.6% in the third quarter. Nisa Investment Advisors LLC now owns 211 shares of the biopharmaceutical company’s stock valued at $45,000 after acquiring an additional 68 shares in the last quarter. Finally, Quest Partners LLC increased its stake in shares of Madrigal Pharmaceuticals by 5,225.0% during the second quarter. Quest Partners LLC now owns 213 shares of the biopharmaceutical company’s stock valued at $60,000 after acquiring an additional 209 shares during the period. 98.50% of the stock is owned by institutional investors.

Madrigal Pharmaceuticals Company Profile

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.